- Aligos Therapeutics Inc ALGS commenced an underwritten public offering of 4 million shares of common stock.
- Underwriters can purchase up to an additional 600k shares.
- J.P. Morgan, Jefferies, and Piper Sandler are acting as the joint book-running managers for the offering.
- Cantor is acting as a lead manager for the offering.
- The proceeds will be used to fund the clinical development of STOPS candidates and R&D activities for siRNA and NASH THR-ß candidates.
- See the offering prospectus here.
- Price Action: ALGS shares are down 7.07% at $22.07 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
